Results 241 to 250 of about 853,702 (263)

Platform Business Model Innovation for Sustainability: A Framework for Industry 5.0 Integration

Business Strategy and the Environment, EarlyView.
ABSTRACT A comprehensive framework is developed for adopting Platform Business Model Innovation (PBMI) to enhance sustainable performance in the Industry 5.0 (I5.0) era. While PBMI plays a growing role in corporate transformation, tensions persist between profit‐driven objectives and broader sustainability imperatives.
Mohamed Ashmel Mohamed Hashim, Issam Tlemsani, Ansarullah Tantry, Songdi Li   +3 more
wiley   +1 more source

Sailing From Penalties to Accountability: Business Strategies and Governance for Firms to Innovate After Environmental Misconduct

Business Strategy and the Environment, EarlyView.
ABSTRACT Firms' continuous pursuit of making a profit in the competitive market may ignore the actions related to environmental responsibilities. This set of actions for financial gains constitutes environmental misconduct, which not only harms ecosystems and communities but also brings reputational damage. Negative press and social media amplification
Ashutosh Singh, Salwa Saleh Almasabi, Ajay Kumar Patel, Priyanka Malik   +3 more
wiley   +1 more source

Establishment of Advanced Regulatory Innovation for Clinical Trials Transformation (ARICTT): a multi-stakeholder public-private partnership-based organization to accelerate the transformation of clinical trials. [PDF]

Transl Clin Pharmacol
Chung WK, Huh KY, Park J, Oh J, Yu KS.
europepmc   +1 more source

Reputational Risk: An Investigation Into How Environmental Failures Drive Stock Price Crashes

Business Strategy and the Environment, EarlyView.
ABSTRACT The study examines the relationship between stock price crashes and firm environment reputational risk. Using a large sample of US listed firms, covering a time span from 2007 to 2021, we test the effect of environmental reputation risk on three measures for the stock price crash risk (NEGCSK, DRUV, and CRASH).
Man Dang, Premkanth Puwanenthiren, Edward Jones, Hoang Long Phan, Abdelhafid Benamraoui   +4 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

New approaches to global health governance: The evolution to public–private partnerships

Journal of Commercial Biotechnology, 1969
Global health issues that transcend geopolitical borders are altering the nature of global health governance. Sovereign nations are more connected than ever and increasingly exposed to trans-border health risks. Traditional global health governance may not account for involvement of multi-level global health actors such as civil-society ...
James Balcius, Thomas E Novotny
openaire   +1 more source

Promoting online drug safety: Using public–private partnerships to deter illicit online drug sales

Journal of Commercial Biotechnology, 1969
Illicit online pharmacies selling counterfeit drugs in a global virtual marketplace remain a critical problem in global health. Yet they continue to operate with little regulation while growing numbers of consumers access the Internet for health information that may lead them to purchase dangerous drugs online.
Timothy K Mackey, Bryan A Liang
openaire   +1 more source

Public–private partnerships in global health

Journal of Commercial Biotechnology, 1969
This issue of the Journal of Commercial Biotechnology includes the papers from the seventh Annual San Diego Health Policy Conference, ‘Public–Private Partnerships in Global Health’, held on 25 March 2011. The San Diego Heath Policy Conference is sponsored by the Institute of Health Law Studies California Western School of Law, in ...
openaire   +1 more source

Biotechnology in India: Public–private partnerships

Journal of Commercial Biotechnology, 2007
As the purpose of this study was a survey of public sector–private industry collaborations of the biotechnology sector in India, an organisational and functional overview of this sector was needed. Therefore, rather than studying a hypothetical biotech sector in India, the focus of this work was to study the public–private partnerships (PPP ...
openaire   +1 more source

Public–private partnerships in addressing counterfeit medicines: The development of the Partnership for Safe Medicines and the Partnership for Safe Medicines-India

Journal of Commercial Biotechnology, 1969
The global drug supply chain has resulted in tremendous vulnerabilities. Despite individual country efforts, both developed and resource-poor countries have experienced tremendous challenges with ensuring safety of the drug supply. In this piece, the formation of a novel public–private partnership (PPP), the Partnership for Safe Medicines (PSM),
openaire   +1 more source